Novo Nordisk reported a surge in earnings and revenue on Thursday as it continues to benefit from the popularity of its weight-loss drugs. However, the company is still struggling with raising the supply of the drugs to meet demand.
Source: finance.yahoo.com
Related posts:
Daily Spotlight: A Pause, For Now
Here Are My 3 Top Tech Stocks to Buy Right Now
Avoid Capital Gains Tax When Selling a House
The crypto billionaire who helped expose SBF’s insolvency calls him ‘one of the greatest fraudsters ...
Here are the worst-performing U.S. stocks as the Evergrande crisis rattles investors